Cantargia's CAN10: Promising Phase 1 Data and FDA Nod Pave Way for HS Trial

Cantargia's CAN10 antibody has shown promising results in its phase 1 clinical trial, with the first multiple dose cohort indicating potential for 4-weekly dosing. The company has also received positive feedback from the FDA and key opinion leaders, further bolstering its development plans for the treatment of hidradenitis suppurativa (HS).



The first multiple dose cohort in healthy participants has provided exposure profiles that align with the single dose phase data, supporting the feasibility of 4-weekly dosing for CAN10. This is a significant milestone, as it could lead to improved patient convenience and compliance compared to more frequent dosing regimens. Cantargia is now planning to perform further evaluations and simulations to confirm this dosing regimen once the complete PK data are available.

Cantargia has also received positive feedback from the FDA following a pre-IND meeting. The FDA considered the proposed phase 2 study design in HS to be reasonable, with the primary endpoint clarified to align with regulatory approval expectations. Cantargia will incorporate additional comments from the FDA into the final protocol to strengthen the study design.

A scientific advisory board (SAB) consisting of clinical US and European experts has provided strong support for the development of CAN10 in the treatment of HS. The SAB emphasized the high unmet medical need for additional treatment options in HS and validated Cantargia's focus on developing CAN10 for this indication. Their feedback on study population and endpoints was consistent with that of the FDA, ensuring that Cantargia is on the right track in terms of patient selection and relevant endpoints for the phase 2 trial.



Cantargia's CAN10 antibody has the potential to revolutionize the treatment of HS, a chronic inflammatory skin condition that affects millions of people worldwide. With promising phase 1 data, positive FDA feedback, and strong support from key opinion leaders, Cantargia is well-positioned to advance its CAN10 program and demonstrate clinical proof of concept in the upcoming phase 2 clinical trial.

As an investor, it's essential to stay informed about the latest developments in the biotechnology sector, particularly when it comes to promising treatments for unmet medical needs. Cantargia's CAN10 antibody has the potential to make a significant impact on the lives of HS patients, and its progress through the clinical trial pipeline is a strong indicator of the company's commitment to developing innovative therapies. Keep an eye on Cantargia as it continues to advance its CAN10 program and potentially transform the treatment landscape for HS.